Anavex Life Sciences has published a study demonstrating the sigma-1 receptor’s role in Alzheimer’s disease. The data contained in it supports the New York-based company’s development of compounds stimulating this receptor as a way of treating the illness. The study, “Sigma-1 Receptor Agonists Induce Oxidative Stress…
Alzheimer’s patients who take benzodiazepines for anxiety, agitation, and insomnia are at a 40 percent greater risk of death than those who don’t take the therapies, a study reports. The research, “Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study,” was published in…
Doctors tend to miss Alzheimer’s diagnosis in psychotic patients more likely than than non-psychotic ones, according to new research by Canada’s University of Toronto. The study, “Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer’s disease,” appeared in the journal Alzheimer’s & Dementia:…
Some people lose their sense of smell before they begin developing Alzheimer’s disease. New York researchers decided to treat older people who had lost their sense of smell and who had mild cognitive impairment for Alzheimer’s before signs of the disease showed up. The treatment led to improvement in their…
The National Institutes of Health (NIH) awarded a $4 million, five-year grant to a project that will investigate — among older residents of a multicultural New York neighborhood — the potential of a healthy and anti-inflammatory diet in lowering the risk of Alzheimer’s disease and cognitive decline. Yasmin Mossavar-Rahmani,…
New York researchers have found a link between sleep apnea and high levels of the amyloid protein that is associated with Alzheimer’s disease. The connection indicates that doctors should check for sleep apnea in older people who display no Alzheimer’s symptoms, the team said. The study, published in the American…
As the number of Americans with Alzheimer’s disease continues to soar, the Global Alzheimer’s Platform (GAP) Foundation is establishing a new model to speed Alzheimer’s clinical trials and increase participation in research. To achieved its goal, the foundation is launching various measures to slash trial cycle times by up…
Billionaire Bill Gates is joining efforts to develop new treatments for Alzheimer’s disease. Gates made the announcement in a recent blog post in which he outlined five areas where more research focus is needed. As a first step toward his commitment, Gates is investing $50 million in the…
Cognition Therapeutics’ lead drug candidate for mild-to-moderate Alzheimer’s disease (AD), CT1812, was shown to be well-tolerated and to lower brain levels of proteins involved in the disease, the company reports. These results, part of a Phase 1b/2a clinical trial, were given in an oral presentation at the recent 10th…
A novel strategy using healthy plasma infusions led to promising results in patients with mild to moderate Alzheimer’s disease, Alkahest recently announced. Stanford Medicine presented clinical data of its PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (NCT02256306) Nov. 4 at the 10th Clinical Trials on Alzheimer’s Disease conference in…
Get regular updates to your inbox.